Our latest paper on Intermediate Clinical Endpoints (ICE) for OS in prostate cancer trials: - Abundant new evidence! - For localised PCa, MFS is OK, but biochemical endpoints are NOT! - No ICEs for CRPC, but PFS could be valid for HSPC? sciencedirect.com/science/articl…